Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 1, 2009, Pages 46-54

  Kang, Hye J ^a   Cho, Sang H ^b   Oh, Suk J ^c   Yang, Sung H ^a   Lee, Moon H ^d   Song, Eun Kee ^e   Chung, Hyun C ^f   Na, Im I ^a   Ryoo, Baek Yeol ^a,g  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Inha University Hospital   (South Korea)

^e Chonbuk National University Medical School   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Korea Cancer Center Hospital   (South Korea)

Author keywords

Advanced gastric cancer; Irinotecan; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DEXAMETHASONE; IRINOTECAN; PACLITAXEL; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIPHORA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; KOREA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIODONTAL DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 61749101179     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01191.x     Document Type: Article

References (33)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52: 23-47.
2. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korea central cancer registry program 2000: Based on registered data from 131 hospitals. Cancer Res Treat; 2002: 77-83.
3. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-8.
4. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-91.
6. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996; 7: 137-49.
7. Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-18.
8. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57.
9. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7.
10. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
11. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9.
12. BouchéO, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 2004; 22: 4319-28.
13. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1 st -line advanced gastric cancer patients [Abstract 4003.] Proc Am Soc Clin Oncol 2005; 23.
14. Moehler M, Eimermacher A, Siebler J et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-8.
15. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-6.
16. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-7.
17. Sakata Y, Ohtsu A, Horikoshi N et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-20.
18. Ichikawa W, Takahashi T, Suto K et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 91: 1245-50.
19. Miyamoto S, Boku N, Ohtsu A et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 2000; 17: 653-8.
20. Lenz HJ, Leichman CG, Danenberg KD et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-82.
21. Shirao K, Shimada Y, Kondo H et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-7.
22. Fukushima M, Uchida J, Takechi T et al. Molecular mechanism of down-regulation by CPT-11 of thymidylate synthase highly expressing in gastrointestinal cancer xenografts during combined treatment with oral fluoropyrimidines [Abstract 197]. Pro ECCO 2003; 12.
23. Que BG, Ardalan B, Camptosar Richman S. CPT-11) reduced the thymidylate synthase gene expression in 5-FU-resistant cell line [Abstract 4763]. Proc Am Soc Clin Oncol 2002; 21.
24. Komatsu Y, Takeda H, Masaaki T et al. Phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer [Abstract 683]. Proc Am Soc Clin Oncol 2002; 21.
25. Narahara H, Takiuchi H, Tsujinaka T et al. Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer [Abstract 677]. Proc Am Soc Clin Oncol 2002; 21.
26. Yamada Y, Yasui H, Goto A et al. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol 2003; 8: 374-80.
27. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987; 71: 1079-85.
29. Inokuchi M, Yamashita T, Yamada H et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006; 94: 1130-5.
30. Uedo N, Narahara H, Ishihara R et al. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 2007; 73: 65-71.
31. Kang YK, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. Proc Am Soc Clin Oncol 2006; 24: LBA4018.
32. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215-21.
33. Baek JH, Kim JG, Jeon SB et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1407-11.